Literature DB >> 29290250

Characterization of never-smoking and its association with clinical outcomes in Chinese patients with small-cell lung cancer.

Xiaozhen Liu1, Tao Jiang1, Wei Li1, Xuefei Li2, Chao Zhao2, Jinpeng Shi1, Sha Zhao1, Yijun Jia1, Meng Qiao1, Limin Zhang1, Jiawei Luo1, Guanghui Gao1, Fei Zhou1, Fengying Wu1, Xiaoxia Chen1, Yayi He1, Shengxiang Ren1, Chunxia Su3, Caicun Zhou4.   

Abstract

OBJECTIVES: Small-cell lung cancer (SCLC) has been viewed as a smoking-related disease, with only 2% to 5% patients being never-smokers. This study aimed to investigate the clinical characteristics of never-smoking and its association with treatment outcomes in Chinese SCLC patients in real world.
METHODS: We performed a retrospective study of 303 patients with SCLC and grouped into smokers and never-smokers. The clinical characteristics and treatment outcomes of two groups were collected and compared.
RESULTS: In total, 113 patients with limited-stage (LS) SCLC and 190 patients with extensive-stage (ES) SCLC were enrolled. Sixty-nine (22.8%) patients were never-smokers. Both the median progression-free survival (PFS) and overall survival (OS) were significantly longer in never-smokers than in smokers (PFS, 8.37 vs. 7.10 months, P=0.036; OS, 19.73 vs. 14.40 months, P=0.044) in all populations. Multivariate analysis suggested that never-smoking was a significant favorable prognostic factor for PFS (HR=0.753; P=0.047) instead of OS (HR=0.780; P=0.236) in patients with SCLC. The objective response rate (ORR) to first-line therapy were similar between two group (52.6% vs. 59.4%, P=0.315). Moreover, prophylactic cranial irradiation (PCI) resulted in marginally significantly longer PFS than observation in patients with ES-SCLC who obtained objective response after first-line therapy (10.57 vs. 7.73 months, P=0.075).
CONCLUSION: The current study indicated that never-smokers are increasingly prevalent in Chinese patients with SCLC. Never-smokers with SCLC had significantly longer PFS and OS compared with smokers, and smoking was an independent poor prognostic factor for PFS in patients with SCLC.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Never-smoker; Prophylactic cranial irradiation; Small-cell lung cancer; Survival

Mesh:

Year:  2017        PMID: 29290250     DOI: 10.1016/j.lungcan.2017.11.022

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  8 in total

1.  Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial.

Authors:  Ying Cheng; Liang Han; Lin Wu; Jun Chen; Hongmei Sun; Guilan Wen; Yinghua Ji; Mikhail Dvorkin; Jianhua Shi; Zhijie Pan; Jinsheng Shi; Xicheng Wang; Yuansong Bai; Tamar Melkadze; Yueyin Pan; Xuhong Min; Maksym Viguro; Xingya Li; Yanqiu Zhao; Junquan Yang; Tamta Makharadze; Ekaterine Arkania; Wenying Kang; Qingyu Wang; Jun Zhu
Journal:  JAMA       Date:  2022-09-27       Impact factor: 157.335

2.  Characteristics and clinical outcomes of patients with nonsmoking small cell lung cancer in Korea.

Authors:  Hye Seon Kang; Jung Uk Lim; Chang Dong Yeo; Chan Kwon Park; Sang Haak Lee; Seung Joon Kim
Journal:  BMC Pulm Med       Date:  2022-05-18       Impact factor: 3.320

Review 3.  Lung cancer in never smokers-the East Asian experience.

Authors:  Fei Zhou; Caicun Zhou
Journal:  Transl Lung Cancer Res       Date:  2018-08

4.  Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study.

Authors:  Ying Cheng; Qiming Wang; Kai Li; Jianhua Shi; Ying Liu; Lin Wu; Baohui Han; Gongyan Chen; Jianxing He; Jie Wang; Donghua Lou; Hao Yu; Shanchun Wang; Haifeng Qin; Xiaoling Li
Journal:  Br J Cancer       Date:  2021-05-18       Impact factor: 7.640

5.  Association of Smoking With Patient Characteristics and Outcomes in Small Cell Lung Carcinoma, 2011-2018.

Authors:  Jeng-Sen Tseng; Chun-Ju Chiang; Kun-Chieh Chen; Zhe-Rong Zheng; Tsung-Ying Yang; Wen-Chung Lee; Kuo-Hsuan Hsu; Yen-Hsiang Huang; Tsang-Wu Liu; Jiun-Yi Hsia; Gee-Chen Chang
Journal:  JAMA Netw Open       Date:  2022-03-01

6.  Synchronous bone metastasis in lung cancer: retrospective study of a single center of 15,716 patients from Tianjin, China.

Authors:  Xu Guo; Wenjuan Ma; Haixiao Wu; Yao Xu; Dezheng Wang; Shuang Zhang; Zheng Liu; Vladimir P Chekhonin; Karl Peltzer; Jin Zhang; Xin Wang; Chao Zhang
Journal:  BMC Cancer       Date:  2021-05-26       Impact factor: 4.430

7.  Survival and pretreatment prognostic factors for extensive-stage small cell lung cancer: A comprehensive analysis of 358 patients.

Authors:  Li-Ling Huang; Xing-Sheng Hu; Yan Wang; Jun-Ling Li; Hong-Yu Wang; Peng Liu; Jian-Ping Xu; Xiao-Hui He; Xue-Zhi Hao; Pei-Di Jiang; Yu-Tao Liu; Jian Luo; Sheng-Yu Zhou; Jin-Wan Wang; Jian-Liang Yang; Yan Qin; Peng Yuan; Lin Lin; Yuan-Kai Shi
Journal:  Thorac Cancer       Date:  2021-05-09       Impact factor: 3.500

8.  Prognostic value of pretreatment smoking status for small cell lung cancer: A meta-analysis.

Authors:  Liling Huang; Yuankai Shi
Journal:  Thorac Cancer       Date:  2020-09-22       Impact factor: 3.500

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.